Equities

Bausch Health Companies Inc

Bausch Health Companies Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CAD)10.05
  • Today's Change0.49 / 5.13%
  • Shares traded1.30m
  • 1 Year change-72.47%
  • Beta1.3056
Data delayed at least 15 minutes, as of Sep 26 2022 21:00 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Bausch Health Companies Inc. is a specialty pharmaceutical and medical device company. The Company develops, manufactures, and markets, primarily in the therapeutic areas of eye health, gastroenterology (GI), and dermatology, a range of branded, generic and branded generic pharmaceuticals, over the counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices) which are marketed directly or indirectly in approximately 100 countries. The Company operates through five segments: Bausch + Lomb, Salix, International, Solta Medical, and Diversified Products. The Bausch + Lomb segment consists of global sales of Bausch + Lomb Vision Care, Consumer, Surgical, and Ophthalmic Pharmaceuticals products. The Salix segment consists of sales in the United States of gastrointestinal (GI) products. The Solta Medical segment consists of global sales of Solta aesthetic medical devices.

  • Revenue in CAD (TTM)11.25bn
  • Net income in CAD59.05m
  • Incorporated2013
  • Employees19.60k
  • Location
    Bausch Health Companies Inc2150 Saint-Elzear Blvd WLAVAL H7L 4A8CanadaCAN
  • Phone+1 (514) 744-6792
  • Fax+1 (514) 744-6792
  • Websitehttps://www.bauschhealth.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Cronos Group Inc129.49m-149.21m1.48bn626.00--0.829--11.44-0.3967-0.39640.34584.680.05952.176.15206,848.70-6.8913.51-7.4515.3913.00-36.30-115.91421.2525.16--0.00--59.32181.87-445.76--60.54--
BELLUS Health Inc21.97k-97.19m1.53bn40.00--4.17--69,486.98-1.07-1.070.00023.390.00008--0.0308549.28-34.50-29.27-37.09-30.98-----442,331.30-64,780.43----0.0027--6.67-59.28-124.28------
Canopy Growth Corp494.23m-2.78bn1.83bn3.15k--0.9302--3.70-6.99-6.991.254.050.09432.325.93156,848.90-53.38-15.43-57.02-16.65-44.85-5.45-566.13-234.003.43-9.840.4864---4.8267.1482.68--10.25--
Bausch Health Companies Inc11.25bn59.05m3.67bn19.60k62.81--1.780.32660.160.1631.09-2.630.28152.165.04573,941.600.1993-3.500.2485-4.0771.4871.800.708-14.220.86931.000.9885--5.07-2.71-69.29---0.556--
Data as of Sep 26 2022. Currency figures normalised to Bausch Health Companies Inc's reporting currency: Canadian Dollar CAD
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.